- Home
- RGC vs GH Comparison
RGC vs GH Comparison
Compare RGC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RGC | GH |
|---|---|---|
| Founded | 2014 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.5B | 12.7B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RGC | GH |
|---|---|---|
| Price | $28.63 | $94.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $119.79 |
| AVG Volume (30 Days) | 90.1K | ★ 1.8M |
| Earning Date | 10-31-2025 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | N/A | $28.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $9.39 | $36.36 |
| 52 Week High | $950.00 | $120.74 |
Technical Indicators
Market Signals| Indicator | RGC | GH |
|---|---|---|
| Relative Strength Index (RSI) | 51.34 | 55.86 |
| Support Level | $25.41 | $89.32 |
| Resistance Level | $29.26 | $101.77 |
| Average True Range (ATR) | 2.18 | 5.14 |
| MACD | -0.17 | 1.00 |
| Stochastic Oscillator | 47.88 | 74.63 |
Price Performance
Historical ComparisonAbout RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
About GH Guardant Health Inc.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.